Leukoreduction on the agenda at US public health meeting in July:
This article was originally published in Clinica
US public health officials have scheduled a public workshop on July 20 in Bethesda, Maryland, to discuss the latest developments in leukoreduction. Topics will include observed clinical adverse events and manufacturing failures, the FDA's current thinking about quality control tests and standards for the procedure, and new scientific developments in filtration, including developing a way to remove prions from blood. The workshop will be sponsored jointly by the FDA, the US National Heart Lung and Blood Institute and the Office of Public Health and Science in the US Department of Health and Human Services. For more information, or to register, contact Rhonda Dawson at the FDA's biologics centre, on tel: +1 301 827 3514; email: firstname.lastname@example.org
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.